Stina Wickström

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2022;11(1):2093426
Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
Schoutrop E; Renken S; Micallef Nilsson I; Hahn P; Poiret T; Kiessling R; Wickstrom SL; Mattsson J; Magalhaes I
Article: JOURNAL OF IMMUNOLOGY. 2022;209(4):751-759
MHC Class I-Dependent Shaping of the NK Cell Ly49 Receptor Repertoire Takes Place Early during Maturation in the Bone Marrow
Wickstrom SL; Wagner AK; Fuchs S; Elemans M; Kritikou J; Mehr R; Karre K; Johansson H; Brauner H
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arner ESJ; Kiessling R; Wickstrom SL
Article: FRONTIERS IN ONCOLOGY. 2022;12:866763
Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
Kiessling A; Ramanathan K; Nilsson OB; Notari L; Renken S; Kiessling R; Gronlund H; Wickstrom SL
Article: ADVANCED SCIENCE. 2021;8(21):e2101029
Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism
Wu J; Chen Z; Wickstrom SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Journal article: ADVANCED SCIENCE. 2021;8(21)
Interleukin‐33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage‐Mediated Shedding Mechanism (Adv. Sci. 21/2021)
Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: CELLS. 2021;10(2):353
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
Luu K; Patwardhan MV; Zeng Q; Wickstrom SL; Lundqvist A; Schwarz H
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(50):32005-32016
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Eisinger S; Sarhan D; Boura VF; Ibarlucea-Benitez I; Tyystjarvi S; Oliynyk G; Arsenian-Henriksson M; Lane D; Wikstrom SL; Kiessling R; Virgilio T; Gonzalez SF; Kaczynska D; Kanatani S; Daskalaki E; Wheelock CE; Sedimbi S; Chambers BJ; Ravetch JV; Karlsson MCI
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(37):22910-22919
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
He X; Yin X; Wu J; Wickstrom SL; Duo Y; Du Q; Qin S; Yao S; Jing X; Hosaka K; Wu J; Jensen LD; Lundqvist A; Salter AI; Brautigam L; Tao W; Chen Y; Kiessling R; Cao Y
Article: CLINICAL CANCER RESEARCH. 2020;26(16):4289-4301
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Poschke IC; Hassel JC; Rodriguez-Ehrenfried A; Lindner KAM; Heras-Murillo I; Appel LM; Lehmann J; Lovgren T; Wickstrom SL; Lauenstein C; Roth J; Koenig A-K; Haanen JBAG; van den Berg J; Kiessling R; Bergmann F; Flossdorf M; Strobel O; Offringa R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:105-118
Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors.
Wickström S; Lövgren T
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:133-140
Assessment of Antitumor T-Cell Responses by Flow Cytometry After Coculture of Tumor Cells with Autologous Tumor-Infiltrating Lymphocytes.
Melief J; Wickström S; Kiessling R; Pico de Coaña Y
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2766
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
Wickstrom SL; Loevgren T; Volkmar M; Reinhold B; Duke-Cohan JS; Hartmann L; Rebmann J; Mueller A; Melief J; Maas R; Ligtenberg M; Hansson J; Offringa R; Seliger B; Poschke I; Reinherz EL; Kiessling R
Article: CANCER IMMUNOLOGY RESEARCH. 2016;4(2):113-123
Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response
Wagner AK; Wickstrom SL; Tallerico R; Salam S; Lakshmikanth T; Brauner H; Hoglund P; Carbone E; Johansson MH; Karre K
Article: JOURNAL OF IMMUNOLOGY. 2014;192(4):1577-1586
A Genetic Defect in Mice That Impairs Missing Self Recognition Despite Evidence for Normal Maturation and MHC Class I-Dependent Education of NK Cells
Wickstrom SL; Oberg L; Karre K; Johansson MH
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2010;40(3):813-823
In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL-2
Vahlne G; Lindholm K; Meier A; Wickstrom S; Lakshmikanth T; Brennan F; Wilken M; Nielsen R; Romagne F; Wagtmann NR; Karre K; Johansson MH

Alla övriga publikationer

Review: LAKARTIDNINGEN. 2025;122:24084
[Cell therapy with tumor infiltrating lymphocytes; a therapeutic alternative for malignant melanoma and soon also other types of cancer].
L Wickström S; A Nilsson J; Lundqvist A; Helgadottir H; Carneiro A; Ny L; Kiessling R
Review: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2024;12(12):e009409
Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy
O'Reilly A; Zhao W; Wickstrom S; Arner ESJ; Kiessling R
Review: MOLECULAR CANCER. 2022;21(1):206
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong L; Jimenez-Cortegana C; Tay AHM; Wickstrom S; Galluzzi L; Lundqvist A
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: ONCOGENE. 2021;40(2):421-435
Counteracting CAR T cell dysfunction
Poorebrahim M; Melief J; Pico de Coana Y; Wickstrom SL; Cid-Arregui A; Kiessling R
Review: PHARMACOLOGY & THERAPEUTICS. 2020;214:107603
Genetically modified immune cells targeting tumor antigens
Poorebrahim M; Abazari MF; Sadeghi S; Mahmoudi R; Kheirollahi A; Askari H; Wickstrom SL; Poortahmasebi V; Lundqvist A; Kiessling R; Cid-Arregui A
Meeting abstract: CANCER RESEARCH. 2018;78(13):ct032
Adoptive T cell transfer combined with DC vaccination in patients with metastatic melanoma
Wickstrom SL; Lovgren T; Wolodarski M; Edback U; Martell E; Markland K; Nystrom M; Lundqvist A; Jacobsson H; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Review: NANOPARTICLES FOR RATIONAL VACCINE DESIGN. 2016;395:95-114
Dynamic Regulation of NK Cell Responsiveness
Kadri N; Wagner AK; Ganesan S; Karre K; Wickstrom S; Johansson MH; Hoglund P
Doctoral thesis: 2015
NK cells and missing self recognition : genetic control, mhc class i dependent education and potential use in cancer therapy
Wickström S
Conference publication: IMMUNOLOGY. 2012;137:236
Characterization of mice with a deficiency in natural killer cell missing self reactivity
Wickstrom S; Oberg L; Karre K; Johansson MH
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;68(2):214-215
In vivo blocking of an inhibitory NK cell receptor, NKG2A
Wickstrom S; Karre K; Johansson MH

Forskningsbidrag

Personalized cellular immunotherapy focusing on patients with cervical or ovarian cancer
Swedish Research Council
1 January 2024 - 31 December 2026
Wickström, Stina Linnéa – Development of cellular immunotherapy for gynecological cancers
Swedish Cancer Society
1 January 2023

Anställningar

Senior Forskare, Onkologi-Patologi, Karolinska Institutet, 2024-
Biträdande Lektor, Onkologi-Patologi, Karolinska Institutet, 2020-2024

Examina och utbildning

Docent, Experimentell immunologi, Karolinska Institutet, 2024
Medicine Doktorsexamen, Institutionen för mikrobiologi, tumör- och cellbiologi, Karolinska Institutet, 2016

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI